Actively Recruiting
Fecal Microbiota Transplantation in Patients With Multiple Drug Resistant Klebsiella Pneumoniae Pneumonia
Led by luxia Kong · Updated on 2024-12-03
100
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multidrug-resistant Klebsiella pneumoniae (MDR-KP) infections account for 10% of all nosocomial infections, and even with effective antibiotics, the mortality rate is as high as 50%. Intestinal bacteria transplantation can not only treat intestinal diseases, but also inhibit the colonization and proliferation of drug-resistant bacteria. This study explored the therapeutic value of fecal microbiota transplantation in patients with MDR-KP pneumonia.
CONDITIONS
Official Title
Fecal Microbiota Transplantation in Patients With Multiple Drug Resistant Klebsiella Pneumoniae Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Diagnosed with community-acquired or hospital-acquired pneumonia
- Sputum or alveolar lavage fluid tests show multidrug-resistant Klebsiella pneumoniae infection
- Patient or family agrees to participate, provides alveolar lavage fluid and stool samples, consents to fecal microbiota transplantation treatment, and signs informed consent
You will not qualify if you...
- Persistent bronchial asthma, severe lung dysfunction, or inability to tolerate bronchoscopy
- Severe intestinal barrier damage such as sepsis or digestive tract perforation
- Diagnosed with explosive colitis, toxic megacolon, gastroesophageal reflux disease, or peptic ulcer
- Taken probiotics within 6 months
- Unable to tolerate adequate enteral nutrition due to severe diarrhea, intestinal stenosis, bleeding, or fistula
- Significant bleeding risk, severe pulmonary hypertension, superior vena cava obstruction, or risk of aortic aneurysm rupture
- Malignant hypertension, recent myocardial infarction (within 6 months), severe arrhythmia, or heart failure
- Malignant tumors, immune deficiency diseases, or systemic inflammatory diseases
- Recent treatment with high-risk immunosuppressive or cytotoxic drugs for more than 4 weeks
- Severe immunosuppression (adult neutrophils <1500/mm3, child neutrophils <1000/mm3)
- Pregnancy or breastfeeding
- Mental disability or active mental illness preventing informed consent
- Other conditions considered unsuitable by clinicians
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The central Hospital of Wuhan
Wuhan, Hubei, China, 430014
Actively Recruiting
Research Team
L
Luxia Kong, master
CONTACT
S
Shuang Geng, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here